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ABSTRACT 32 
Background: As pharmacokinetics after burn trauma are difficult to predict, we conducted a 33 
3-year prospective, monocentric, randomized controlled trial to determine the extent of under 34 
and overdosing of antibiotics and further evaluate the impact of systematic therapeutic drug 35 
monitoring (TDM) with same day real-time dose adaptation to reach and maintain antibiotic 36 
concentrations within therapeutic range.  37 
 38 
Methods: Forty-five consecutive burn patients treated with antibiotics were prospectively 39 
screened. Forty fulfilled inclusion criteria; after one refusal and one withdraw consent, 19 40 
were randomly assigned to an intervention group (real-time antibiotic concentration 41 
determination and subsequent adaptations), and 19 to a standard-of-care group (antibiotic 42 
administration at physician’s discretion without real-time TDM). 43 
 44 
Results: Seventy-three infectious episodes were analyzed. Before intervention, only 46/82 45 
(56%) initial trough concentrations fell within the range. There was no difference between 46 
groups in initial trough concentrations (adjusted HR=1.39 [95%CI: 0.81-2.39], p=0.227) or 47 
time to reach the target. However, thanks to real-time dose adjustments, trough concentrations 48 
of the intervention group remained more within the predefined range (57/77 [74.0%] vs. 49 
48/85 [56.5%], adjusted OR=2.34 [95%CI: 1.17-4.81], p=0.018); more days were spent 50 
within the target range (193 days / 297 days on antibiotics [65.0%] vs. 171/311 [55.0%], 51 
adjusted OR=1.64 [95%CI: 1.16-2.32], p=0.005); and fewer results were below target trough 52 
concentrations (25/118 [21.2%] vs. 44/126 [34.9%], adjusted OR=0.47 [95%CI: 0.26-0.87], 53 
p=0.015). No difference in infection outcomes was observed between study groups. 54 
 55 
Conclusions: Systematic TDM with same day real-time dose adaptation was effective in 56 
reaching and maintaining therapeutic antibiotic concentrations in infected burn patients, 57 
which prevented both over- and under-dosing. A larger multicentric study is needed to further 58 
evaluate the impact of this strategy on infection outcomes and the emergence of antibiotic 59 
resistance during long-term burn treatment.  60 
 61 
This study was registered with the ClinicalTrials.gov platform on September 27
th
 2013. 62 
Trial Registration: NCT01965340. 63 
 64 
Keywords: pharmacokinetics of antibiotics, burn patients, therapeutic drug monitoring 65 
 66 
 67 
 68 
 69 
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INTRODUCTION 74 
Sepsis is a major cause of morbidity and mortality among burn patients (1-4). Burn patients 75 
often suffer from recurrent infections that are difficult to treat, caused by nosocomial 76 
multidrug-resistant microorganisms (5, 6) . The rapid spread of antibiotic resistance is 77 
currently a major challenge in burn care. As the number of new anti-infective drugs entering 78 
the market is disappointingly low, strategies to preserve the efficacy of currently approved 79 
antibiotics are urgently needed (7, 8). 80 
Antibiotic stewardship programs may reduce the selective pressure induced by antibiotic 81 
misuse (9). In addition to rapidly identifying bacterial infections, systematically de-escalating, 82 
and shortening the duration of antibiotic treatment, these bundles also include the close 83 
monitoring of pharmacokinetic-pharmacodynamic (PK-PD) characteristics to further optimize 84 
antibiotic treatments while decreasing the risk that resistance will develop (10).  85 
Therapeutic drug monitoring (TDM) was introduced into clinical practice primarily to 86 
improve efficacy and to limit the toxicity of antibiotics with narrow therapeutic windows 87 
(e.g., vancomycin, aminoglycosides). However, with the increasing availability of rapid-88 
dosing techniques, the number of drugs that can be measured in the plasma of patients has 89 
grown tremendously over the last decade (11). It is currently possible to monitor blood 90 
concentrations of antibiotics in real-time to improve efficacy and avoid under-dosing, which 91 
can favor bacterial regrowth and the emergence of resistant organisms. Several studies have 92 
demonstrated that TDM improves the prescription of antibiotics in various populations of 93 
hospitalized patients, including critically ill patients, with a direct impact on outcomes (11-94 
17). 95 
Altered metabolism, dramatic fluctuations in drug clearance and rapid modifications in the 96 
volume of distribution make the administration of antibiotics to burn patients particularly 97 
complex. However, no recommendations exist to specifically guide antibiotic dosage after 98 
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burn trauma and only few studies have prospectively and systematically explored antibiotic 99 
PK in such conditions. Recently, we demonstrated that burn patients very often require drastic 100 
modifications of the standard antibiotic doses recommended by the manufacturers to avoid 101 
both under- and over-dosing (15). We conducted a 3-year prospective, monocentric, 102 
randomized, controlled clinical trial to determine the extent of under and overdosing of 103 
antibiotics and further evaluate the impact of systematic TDM with same day real-time dose 104 
adaptation to reach and maintain antibiotic concentrations within therapeutic range.  105 
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MATERIALS AND METHODS 106 
Study design and setting 107 
This prospective, monocentric, randomized, controlled trial was conducted between October 108 
2013 and October 2016 at the Lausanne Burn Intensive Care Unit (BICU), a five-bed Swiss 109 
tertiary reference BICU nested in the 35-bed medico-surgical ICU of the Centre Hospitalier 110 
Universitaire Vaudois (CHUV).  111 
 112 
Ethics 113 
This study was approved by the Commission cantonale d'éthique de la recherche sur l'être 114 
humain (#195/13) and performed in accordance with the Declaration of Helsinki and its later 115 
amendments. It was registered with the https://clinicaltrials.gov/ platform (NCT01965340) 116 
and adherence to good clinical practice and study protocol was regularly monitored by the 117 
Lausanne Clinical Trial Unit. Written informed consent was obtained from all participants or 118 
proxies at the time of enrollment. 119 
 120 
Selection Criteria 121 
All patients admitted to the BICU after burn trauma and receiving intravenous antibiotics 122 
were prospectively screened for inclusion. Patients younger than 14 yr, those who refused 123 
informed consent, those with length of hospital stay <72 hr, and those who were legally 124 
incompetent were excluded (Figure 1). 125 
 126 
Data collection 127 
Patient age, sex, glomerular filtration rate (calculated using the Cockcroft-Gault formula) and 128 
burn severity scores (total body surface area [TBSA] affected, presence of burn inhalation 129 
injury (18, 19), Ryan score, and Simplified Acute Physiology Score [SAPS II]) were collected 130 
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prospectively. All infection episodes corresponding to a monitored antibiotic course were 131 
characterized, as previously described [see supplemental information in (15)]. Concomitant 132 
sites of infection, including sites of primary bloodstream infections, were considered as 133 
separate episodes. Episodes of infection caused by several microorganisms were considered 134 
only once. To guide the pharmacologic recommendation a minimum inhibitory concentration 135 
(MIC) was determined for the causative organism whenever possible.  136 
 137 
Antimicrobial treatment 138 
Information on the date and time of antibiotic administration, dosage and duration of 139 
treatment were prospectively collected from the clinical information system (Metavision

; 140 
IMDsoft, Tel Aviv, Israel). Total antibiotic consumption was reported as defined daily dose 141 
(DDD) (http://www.whocc.no/atc_ddd_index/)(20). Antibiotics were started according to the 142 
manufacturer’s recommendations, with modifications for the calculation of glomerular 143 
filtration rate when appropriate (See Supplemental Material file S2). From October 2013 144 
until July 2015, all antibiotics were given via 30-minute infusion. In August 2015, the 145 
duration of infusion time of β-lactams was increased to 2 hours, starting from the second dose 146 
due to an update of local protocols regarding all critically ill patients, including burn patients, 147 
receiving β-lactams. Because systematic TDM of aminoglycosides and vancomycin are part 148 
of the standard of care at our institution, those treatment courses were not included. 149 
 150 
Intervention 151 
After informed consent was obtained, patients were randomized to an intervention group 152 
(patients with real-time TDM and online antibiotic adaptation) or to a standard-of-care group 153 
(patients for whom antibiotic concentrations would be determined only after completion of 154 
the study). Randomization was stratified according to burn severity (TBSA <20%, 20–40%, 155 
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41–60%, >60%) (Figure 1 and supplemental Figure S1). All infectious episodes and 156 
antibiotic courses during a given patient’s stay were handled according to the initial 157 
randomization result. Blood was drawn from each patient every other day (QOD) for TDM 158 
until the end of the antibiotic course, but antibiotic concentrations were determined in real-159 
time only for patients randomized to the intervention group, for whom the prescription of 160 
antibiotics was further adapted the same day according to a standardized adaptation protocol 161 
by dedicated independent pharmacologists and infectious disease specialists to meet 162 
predefined pharmacodynamic targets (see Supplementary Material adaptation protocol file 163 
S1). An every other day TDM regimen was chosen in order to rapidly adjust the antibiotic 164 
doses while taking into account the time needed for β-lactams to reach the steady state after 165 
dose adaptation. In the standard-of-care group, the prescription of antibiotics was modified at 166 
the clinician’s discretion. Upon clinician’s special request, rescue TDM could however be 167 
determined in real-time for any patient randomized to the standard-of-care group. 168 
 169 
Evaluation of trough antibiotic concentrations 170 
Antibiotic serum levels were determined (2.7 ml blood samples) by the Laboratory of the 171 
Service of Biomedicine at CHUV using a multiplex assay with high-performance liquid 172 
chromatography coupled with tandem mass spectrometry (HPLC-MS/MS) according to 173 
previously published validated analytical methods with lower limits of quantification of 0.02-174 
0.5 mg/L (21, 22). The median total amount of blood withdrawn from each patient reached 175 
13.5 ml 8.1; 25.0.  176 
Total drugs levels were measured, but estimated unbound concentrations were calculated 177 
using available data for protein binding (see our local adaptation protocol file in 178 
Supplementary Material S1). Antibiotic serum levels were obtained within 6 hours on the 179 
day of the request from Monday to Friday and subsequent adaptation of antibiotic prescription 180 
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was performed the same day. On the weekend, blood samples were analyzed and available on 181 
Monday afternoon where the adaptation took place. The empirical dosages used at initiation 182 
of antibiotic therapy are presented in Supplementary Material S2. Trough serum 183 
concentrations of antibiotic had to exceed the MIC of the causative microorganism(s). If the 184 
MIC was not available (e.g. the infection was not microbiologically documented), the MIC90 185 
(according to the European Committee on Antimicrobial Susceptibility Testing database) of 186 
the most frequently occurring Gram-positive and Gram-negative bacteria isolated at our burn 187 
ICU was determined (15, 23) (see Supplemental Material adaptation protocol file S1). The 188 
upper limits of trough concentrations were also specified in the adaptation protocol file.  189 
 190 
Doses adaptations were performed using pre-defined “steps”. The algorithm is presented in 191 
Supplemental Material S1. Briefly, the prescription of the given antibiotic was reduced of 192 
one step in case of excessive trough levels  < 150% of the upper limit, respectively increase of 193 
one step in case of trough levels ranging between 50-100% of the minimal target. 194 
Increase/decrease of two steps was apply in case of trough levels exceeding 150-200% of the 195 
upper limit, respectively ranging between10-50% of minimal target.  196 
 197 
Outcomes 198 
The first predefined primary pharmacokinetic outcomes were the time required to achieve 199 
anti-infective serum concentrations within the predefined target range and the proportion of 200 
trough antibiotic serum concentration measurements that fell within the target range during a 201 
single course of treatment with a given anti-infective agent. Secondary predefined endpoints 202 
included total antibiotic consumption as expressed in DDD, clinical resolution of infectious 203 
episodes and proportion of antibiotic concentration measurements above and below 204 
predefined targets.  205 
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Sample size 206 
We assumed that 50% of patients would remain in the predefined target range without TDM 207 
intervention and that trough concentration measurements would increase this result to 80%. 208 
Therefore, we calculated that the study would need to include a sample of 90 patients 209 
assuming each patient had only one episode of infection and one antibiotic cure ([two-210 
sided]=0.05, β=0.8).  211 
 212 
Statistical analysis 213 
Continuous normally and non-normally distributed variables are reported as means ± standard 214 
deviations and medians with interquartile ranges (p25; p75), respectively. Categorical 215 
variables are reported as frequencies and percentages. An intention-to-treat analysis of all 216 
randomized patients was performed for all endpoints. Per-protocol analysis was performed for 217 
the main outcomes, excluding unblindings for rescue TDM requests in the standard-of-care 218 
group. All analyses were adjusted for burn severity (stratified randomization). Results of 219 
unadjusted analyses are also presented. As there were very few patients with TBSA>60% we 220 
used 3 levels of burn severity for the analysis: TBSA<20%, 20%-40% and >40%. Difference 221 
between groups regarding time to achieve anti-infective concentrations within the predefined 222 
target range was assessed using Cox proportional hazards model. Effect of the intervention on 223 
the proportion of antibiotic concentration measurements that fell within the target was 224 
evaluated with a logistic regression model. To assess the effect of systematic TDM with same 225 
day real-time dose adaptation on the frequency of antibiotic concentrations remaining within 226 
the predefined target range, we first compared the initial concentrations between groups, 227 
before analyzing the impact of intervention on subsequent antibiotic concentration 228 
measurements in each randomization group. Difference between groups in terms of 229 
proportions of antibiotic concentration measurements above the upper limit or below the 230 
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lower limit and proportion of days within the predefined target was assessed using logistic 231 
regression. Analysis of total antibiotic consumption (DDD) was evaluated using robust linear 232 
regression. Significance levels were set at an α-level of 0.05. GraphPad Prism software 233 
(version 5.0d; GraphPad Company, San Diego, CA) and R (version 3.3.2) were used for 234 
statistical analysis (24).   235 
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RESULTS 236 
Patient characteristics  237 
Between October 23, 2013 and October 31, 2016, 45 out of 83 burn patients (54.2%) admitted 238 
to the Lausanne BICU received intravenous antibiotics. Ultimately, 39 (86.7%) of these were 239 
included in the study. One patient withdrew consent after randomization, so that 19 patients 240 
were finally randomized to the intervention group and 19 to the control group (Figure 1). 241 
Burn patients’ characteristics are presented in Table 1. Most of the patients were male 242 
(71.1%), with median age of 55 years [31; 71] and TBSA 20% [13; 35]. Twenty-four out of 243 
38 (63.2%) patients suffered from inhalation injury. The median duration of hospitalization 244 
was 22.5 days [12; 42] with a minimum of 4 days and a maximum of 115 days. Two patients 245 
in the standard-of-care group died (5.3%) after decisions to withdraw therapy.  246 
 247 
Characteristics of infectious episodes 248 
Among 38 randomized patients, we observed 73 episodes of infection, which accounted for 249 
1.9 infection episodes per patient and 41 antibiotic cures per randomization group (Figure 1 250 
and Table 2). The most frequently encountered infections were pneumonia (n=42, 57.5%) 251 
and burn wound infections (n=16, 21.9%) (Tables 2 and 3). There were 62 (84.9%) 252 
microbiologically documented infectious episodes, with the following bacteria isolated most 253 
frequently: Pseudomonas aeruginosa (n=7, 11.3%), Staphylococcus aureus (n=6, 9.7%), and 254 
Streptococcus pneumoniae (n=4, 6.5%) (Figure 2 and Table 2). The antibiotics prescribed 255 
most commonly were meropenem, amoxicillin, piperacillin-tazobactam, and ceftriaxone 256 
(Table 3). The duration of treatment (7 days [4.5; 9]) and antibiotic consumption were similar 257 
between groups (Table 3). 258 
 259 
 260 
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Study endpoints 261 
A total of 244 measurements of antibiotic concentrations were obtained during the study 262 
period: 118 in the intervention group and 126 in the standard-of-care group (Tables 2, 3 and 263 
Supplemental Material S3). The MIC of the causative organism could be set as the target for 264 
53 out of 73 (73%) episodes of infection (Table 2). Before intervention, (i.e. at first 265 
measurement of each antibiotic course), only 46/82 (56%) initial trough concentrations fell 266 
within the range, without difference between groups (22/41 [53.7%] in the intervention group 267 
vs. 24/41 [58.5%] in the standard of care group) (Table 2). Following the intervention, the 268 
numbers of through levels within the target was higher in the intervention group when 269 
considering all subsequent measurements (57/77 [74.0 %] vs. 48/85 [56.5%] adjusted 270 
OR=2.34 95%CI: 1.17-4.81, p=0.018, unadjusted OR=2.20 95%CI: 1.14-4.33, p=0.021) 271 
(Tables 2 and 3). There was no difference between groups regarding the time to reach the 272 
target (adjusted HR=1.39 95%CI: 0.81-2.39, p=0.227, unadjusted HR=1.29 95%CI: 0.77-273 
2.16, p=0.341). For 17 antibiotic cures (9 in the standard-of-care group and 8 in the 274 
intervention group) there was no other measurement after the first one due to antibiotic 275 
switches (de-escalation n=9, escalation n=3), patients’ transfers n=4 or end of therapy 276 
n=1.  277 
Patients in the intervention group spent more days within the predefined target range than did 278 
patients in the standard-of-care group (193 out of 297 days on antibiotic [65.0%] vs. 171 out 279 
of 311 days on antibiotic [55.0%], adjusted OR=1.64 [95%CI: 1.16-2.32], p=0.005, 280 
unadjusted OR=1.52 [95%CI: 1.10-2.11], p=0.012). The number of measurements below the 281 
lower limit was significantly higher among standard-of-care patients (25/118 [21.2%] vs. 282 
44/126 [34.9%], adjusted OR=0.47 [95%CI: 0.26-0.87], p=0.015, unadjusted OR=0.50 283 
[95%CI: 0.28-0.88], p=0.018)(Tables 2 and 3) while the number of antibiotic concentrations 284 
measurements above the upper limit was similar between groups (13/118 [11.0%] vs. 10/126 285 
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[7.9%], adjusted OR=1.48 [95%CI: 0.60-3.74], p=0.399, unadjusted OR=1.44 [95%CI: 0.61-286 
3.50], p=0.412)(Tables 2 and 3). Young severely burn patients, especially when presenting 287 
with renal hyperclearance, were frequently - and sometimes repeatedly - below the therapeutic 288 
target (Table 2). Total antibiotic consumption (DDD) was not statistically different between 289 
groups (β adjusted=-0.34 [95%CI: -5.04-4.38], p=0.886, β unadjusted=-0.94 [95%CI: -5.45-290 
3.56], p=0.677). No difference in infection outcomes was observed (33 successful episodes / 291 
36 episodes of infection [91.7%] in the intervention group vs. 30 successful episodes / 31 292 
episodes of infection [96.8%] in the standard-of-care group). 293 
 294 
Rescue TDM 295 
In the standard-of-care group, 6 measurements of trough levels necessitated rescue in 3 296 
patients with severe burns (TBSA 60%; meropenem [n=3], ertapenem [n=1], 297 
piperacillin/tazobactam [n=2]). Two trough-level measurements were below the target range, 298 
and both resulted in prescription changes: one increase in drug dosage and one antibiotic 299 
switch (see Supplemental Material S4 for more details). After removing the 3 patients for 300 
whom rescue TDM was requested from the analysis, intervention: (i) increased the frequency 301 
of trough level measurements within the predefined target range (57/77 [74.0%] vs. 35/68 302 
[51.5%], adjusted OR=2.69 [95%CI: 1.32-5.57], p=0.007, unadjusted OR=2.69 [95%CI: 1.35-303 
5.46], p=0.005), (ii) did not reduce the time needed to reach the target (adjusted HR=1.41 304 
[95%CI: 0.81-2.44], p=0.225, unadjusted HR=1.32 [95%CI: 0.77-2.25], p=0.313).  305 
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DISCUSSION 306 
This 3-year prospective monocentric, randomized controlled trial demonstrated that real-time 307 
TDM with same day dose adaptation was effective in reaching, maintaining therapeutic 308 
trough levels and avoiding underdosing in infected burn patients. At initiation of antibiotic 309 
therapy, less than 60% of patients had an adequate antibiotic trough level. However, burn 310 
patients that benefited from the intervention subsequently spent more days within the 311 
predefined target range than did patients treated with the standard-of-care. This effect held 312 
true regardless of burn severity. 313 
To our knowledge, this is the first randomized prospective study showing that a 314 
pharmacokinetic intervention guided on real-time TDM in patients with severe burns 315 
requiring admission to the ICU effectively improves the probability of being within 316 
therapeutic range during antibiotic treatment. Over a one-year period, Patel et al. conducted a 317 
prospective study evaluating the impact of TDM in burn patients treated with β-lactams in a 318 
ward environment (25). The authors excluded critically ill burn patients and did not stratify 319 
the randomization according to burn severity. The results of the study showed that empiric β-320 
lactam dosing did not consistently achieve therapeutic targets and displayed significant 321 
variability in trough antibiotic concentrations after burn trauma. 322 
 323 
Our population of burn patients requiring ICU admission was similar to those previously 324 
described by others in terms of age, inhalation injury, and burn severity (25-30). As we and 325 
others have reported, sepsis after burn trauma is typically caused by pneumonia or infections 326 
of burn wounds (31-35). Such infections are typically due to P. aeruginosa and S. aureus (7, 327 
8). While broad-spectrum antibiotics are among those prescribed most frequently to fight 328 
infection, the use of imipenem-cilastatin in comparison to meropenem was surprisingly 329 
uncommon, probably because of the former’s greater variability in trough concentration we 330 
 o
n
 February 6, 2018 by Universitaetsbibliothek Bern
http://aac.asm
.org/
D
ow
nloaded from
 
 15 
 
reported (15). Burn trauma differentially affected the pharmacokinetics of highly protein-331 
bound antibiotics: while ceftriaxone trough concentrations were mostly within the target 332 
range, flucloxacillin trough levels often fell below the predefined target range, probably as a 333 
consequence of increased clearance in burn patients (36, 37). In one case, this effect may have 334 
been the result of a physician’s underdosage (2 g 3×/day vs. standard recommended dosage of 335 
2 g 4–6×/day). 336 
 337 
Our study protocol allowed physicians to ask for rescue TDM in cases of poor clinical 338 
evolution. Per physician special request, 6 rescue measurements of trough concentrations 339 
were obtained for 3 severely burned patients presenting with affected TBSA ≥60%. These 340 
interventions resulted in an increased dose of antibiotics in one case and an antibiotic switch 341 
in the second case. These unblinded requests may highlight the importance of TDM in this 342 
complex population of patients and suggest that systematic TDM, still available on request for 343 
clinicians, has progressively become the standard of care at our BICU, especially after severe 344 
burn trauma. After removing these patients from subsequent analyses, per-protocol analysis 345 
confirmed the results of the intention-to-treat analysis and the effect of real-time TDM. 346 
 347 
Our study has several strengths. First, it is a prospective and randomized study that included 348 
consecutive burn patients admitted to a tertiary hospital BICU over the course of 3 yr. 349 
Second, our study benefited from an experienced team of certified pharmacologists and 350 
infectious disease specialists who have pioneered the analysis and interpretation of antibiotic 351 
concentrations (15, 38, 39). Third, many different infections have been documented and 352 
analyzed during this 3-year study period. Fourth, despite the evolution of clinical practice 353 
over the 3-yr study period in ways that may have lowered the full effects and benefits of TDM 354 
(e.g., the introduction of an increased perfusion duration for β-lactam maintenance doses as 355 
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standard of care for all critically ill patients under β-lactams at our institution), the results of 356 
this study demonstrate a significant impact of real-time TDM with online antibiotic dose 357 
adaptation on the prescription of antibiotics to burn patients. 358 
 359 
This study also has some limitations. First, it was monocentric. Second, we observed a 360 
decrease in the number of admissions since 2013, which explains why the number of 361 
infectious episodes was lower than expected (15). Third, if MIC could be obtained for most of 362 
the documented infections, it was available at time of time adaptation only in few cases. 363 
Fourth, as we performed trough levels and not in the mid-interval trough levels, time above 364 
MIC could not be estimated. Finally, because we randomized patients rather than infectious 365 
episodes to facilitate the acquisition of informed consent, we observed a slight imbalance 366 
between groups in the number of trough concentration measurements. This discrepancy may 367 
also reflect the antibiotic switch (executed for de-escalation) or the longer duration of 368 
antibiotic treatment in patients with drug-resistant bacteria.  369 
 370 
In conclusion, through a 3-year prospective, monocentric, randomized, controlled trial we 371 
demonstrated that systematic TDM with same day antibiotic dose adaptation is a feasible and 372 
useful intervention in order to overcome pharmacokinetic variability after burn trauma, 373 
thereby avoiding antibiotic under- and over-dosage. This monitoring should especially be 374 
considered in the subset of patients presenting with augmented renal clearances after burn 375 
trauma (40-44). TDM for most β-lactam antibiotics is now routinely available at our BICU, 376 
and we further modified our internal guidelines to also perform systematic TDM in other 377 
groups of ICU patients, such as those under extracorporeal membrane oxygenation support. 378 
Nevertheless, further studies are needed to evaluate whether this intervention can improve 379 
clinical outcome and limit the emergence of antibiotic resistance. 380 
381 
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LIST OF ABBREVIATIONS 382 
BICU    Burn Intensive Care Unit 383 
GFR   Glomerular Filtration Rate 384 
HPLC- MS/MS High Performance Liquid Chromatography coupled with tandem Mass 385 
Spectrometry 386 
ICU Intensive Care Unit 387 
MIC   Minimum Inhibitory Concentration 388 
PK   Pharmacokinetic 389 
PD   Pharmacodynamic 390 
QOD   Every other day 391 
TABI   Time After Burn Injury 392 
TBSA   Total Body Surface Area 393 
TDM   Therapeutic Drug Monitoring 394 
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FIGURE LEGENDS 573 
Figure 1: Study flow-chart. 574 
TDM: Therapeutic Drug Monitoring 575 
TBSA: Total Body Surface Area 576 
 577 
Figure 2: Isolated microorganisms. 578 
 579 
TABLE LEGENDS 580 
Table 1: Burn patients’ characteristics. 581 
Table 2: Characteristics of infectious episodes and antibiotic concentrations 582 
Table 3: Study outcomes. 583 
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Randomized 
(n = 39) 
Patients treated with 
antibiotics (n = 45)  
Intervention group: 
Patients with unblinded TDM 
Exclusion criteria : 
Psychiatric condition (n = 3), 
Extended time since burn injury 
(transferred patient for 
continuation of care) (n = 1), 
Family refusal (n = 1), and 
Death (n = 1). 
n = 19 
TBSA < 20% (n = 8) 
TBSA 20–40% (n = 8) 
TBSA 41–60% (n = 2) 
TBSA > 60% (n = 1) 
Admission for burn trauma  
(n = 83)  
Standard-of-care group: 
Patients with blinded TDM  
n = 19 
TBSA < 20% (n = 10) 
TBSA 20–40% (n = 6) 
TBSA 41–60% (n = 2) 
TBSA > 60% (n = 2) 
Withdraw 
consent  
(n = 1) 
40 episodes of infection 
41 antibiotic cures 
297 days with antibiotics 
118 trough levels 
33 episodes of infection 
41 antibiotic cures 
311 days with antibiotics 
126 trough levels 
Figure 1: Study flow-chart 
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Figure 2: Isolated microorganisms 
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Table 1: Burn patients' characteristics 
 
 
 
Characteristics All patients Patients with unblinded TDM Patients with blinded TDM 
  (Intervention group)  (Standard-of-care group)   
Number of patients (n) 38 19 19 
Male, n (%) 27 (71.1) 15 (78.9) 12 (63.2) 
Age (yrs, median [p25; p75]) 55.0 [31.0; 71.3] 61.0 [32.0; 72.0] 51.0 [24.0; 69.0] 
Admission weight (kg, median [p25; 
p75]) 
74.5 [67.0; 86.9] 80.0 [68.0; 95.0] 71.1 [67.0; 84.1] 
TBSA affected (%) (median [p25; p75]) 20.0 [12.8; 35.3] 20.0 [13.0; 25.0] 21.5 [12.0; 36.0] 
< 20 (n, %) 17 (44.7) 8 (42.1) 9 (47.4) 
20-40 (n, %) 13 (34.2) 8 (42.1) 6 (31.6) 
41-60 (n, %) 5 (13.2) 2 (10.5) 2 (10.5) 
> 60 (n, %)   3 (7.9)    1 (5.3)   2 (10.5) 
SAPS II (median [p25; p75]) 29.5 [21.5; 42.8] 31.0 [22.0; 42.0] 28.0 [20.0; 45.0] 
Ryan score (mean ± SD)  1.2 ± 0.7  1.3 ± 0.6  1.0 ± 0.8 
Inhalation lesions, n (%)  24 (63.2)  13 (68.4)  11 (57.9) 
Length of stay (days, median [p25; p75]) 22.5 [12.0; 42.0] 27.0 [13.0; 45.0] 20.0 [12.0; 40.0] 
  Mortality in the BICU, n (%)  2 (5.3)  0 2 (10) 
 
BICU: Burn Intensive Care Unit; SAPS II: Simplified Acute Physiology Score II; SD: Standard Deviation; TBSA : Total Body Surface Area; TDM: Therapeutic Drug 
Monitoring. 
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Table 2: Characteristics of infectious episodes and antibiotic concentrations 
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Intervention group 
19 M 41 #1 Pneumonia (H. influenzae) ceftriaxone D1 No 40.8 No / / 
      #2 Burn wound (E. coli) meropenem D1 No 8.9 ↑ Decrease 0.015 0.015 
          
  D2 Yes 17.7 ↑ Already adapted     
          
  D4 Yes 7.7 No     
          
  D6 Yes 4.3 No     
          
  D8 Yes 6.3 No     
      
 
  
  D10 Yes 9.6 ↑ No     
89 F 20 #3 Burn wound (S. aureus) cefazoline D2 Yes 55.1 No 0.006 0.06 
          
  D4 Yes 32.3 No     
          
  D6 Yes 36.5 Decrease a     
          
  D8 Yes 16.7 No     
          
  D10 Yes 16.1 No     
19 M 40 #4 Pneumonia (S. pneumoniae) amoxicillin D2 Yes 3.3 Increase 0.094 0.117 
        Pneumonia (S. pneumonia, S. aureus) amox-clav. D4 No 8.9 No 0.094 / - 0.117 / - 
      #5 Pneumonia (C. koseri) meropenem D2 No 2.5 No 0.008 0.008 
            D3 No 1.3 ↓ Increase     
          
  D4 Yes 1.5 No     
            D6 Yes 3.7 Increase     
            D8 Yes 22.5 ↑ AB switch     
      #6 Sepsis  pip-tazo D2 No 34.2 / 4.5 ↑ No / / 
        (non identified microorganism)   D4 No 43.6 / 6.4 ↑ No     
          
  D6 No 75.7 / 25.5 ↑ No     
          
  D8 No 31.0 / 23.2 No     
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57 M 25 #7 Pneumonia (S. aureus) amox-clav. D2 No 2.9 ↓ Increase 0.5 0.625 
          
  D4 Yes 4.7 No     
          
  D6 Yes 3.6 No     
          
  D8 Yes 3.8 No     
35 F 15 #8 Pneumonia (S. aureus) flucloxacillin D5 No 0.5 ↓ No 
not in 
routine  not in routine  
71 F 18 #9 Pneumonia (E. aerogenes, B. fragilis)  meropenem D2 Yes 10.8 ↑ Decrease 0.06 / 0.015 0.06 / 0.015 
          
  D5 Yes 7.9 No     
          
  D6 Yes 7.1 No     
      #10 Peritonitis (E. aerogenes, B. fragilis) meropenem  D8 Yes 5.0 No 0.06 / 4 0.06 / 4 
          
  D11 Yes 8.2 No     
          
  D14 Yes 12.1 ↑ No     
      
#11 Burn wound (E. aerogenes, S. epidermidis) imipenem D2 No 1.4 / 5.6 b No 0.5 / - 0.625 / - 
          
  D4 No 1.9 / 7.8 b No     
          
  D6 No 3.1 / 12.3  No     
          
  D8 No 2.8 / 11.0  No     
          
  D10 No 2.6 / 9.7  No     
81 M 6 #12 Pneumonia (S. pneumoniae) ceftriaxone D4 Yes 17.2 No 0.008 0.08 
            D6 Yes 18.4 No     
            D8 Yes 26.1 No     
62 M 2 #13 Pneumonia (E. coli, S. pneumoniae) ceftriaxone D2 Yes 23.7 No 0.25 / 1.00 2.5 / 10.00 
            D5 Yes 33.0 No     
66 F 20 #14 Burn wound (P. aeruginosa) meropenem D2 Yes 1.3 No 0.25 0.25 
          
  D4 Yes 0.7 No     
          
  D6 Yes 1.0 No     
          
  D8 Yes 0.7 No     
32 M 13 #15 Pneumonia (S. pneumoniae) amox-clav. D2 Yes 1.0 No 0.03 0.037 
          amoxicillin D4 Yes 0.7 No     
            D6 Yes 0.8 No     
72 M 23 #16 Pneumonia (oropharyngeal flora) amox-clav. D2 No 44.6 ↑ No / / 
            D4 No 1.3 ↓ No     
            D6 No 1.2 ↓ No     
76 M 5 #17 Pneumonia (K. oxytoca, S. aureus) pip-tazo D5 No 1.4 / 1.0 ↓ Increase 1.0 / - 1.54 / - 
            D6 No 3.7 / 1.3 ↓ No     
      #18 Burn wound  meropenem D2 No 3.6 No / / 
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        (non identified microorganism)   D4 No 6.5 No     
      
      D6 No 10.7 No     
      #19 Pneumonia (MSSA, P. mirabilis, K. pneumoniae) pip-tazo D1 No 77.7 / 15.2 ↑ AB switch / / 
          ceftriaxone / No / / / / 
      #20 Sepsis (non identified microorganism) meropenem D1 No 10.9 No / / 
            D2 No 11.7 No     
68 M 25 #21 Pneumonia (H. influenzae) meropenem D1 No 2.6 No 0.25 0.25 
            D2 Yes 1.8 No     
            D4 Yes 1.2 No     
          amox-clav.  D2 Yes 13.1 No 2.0 2.5 
        
    D4 Yes 8.4 No     
        
    D6 Yes 17.1 No     
      #22 Pneumonia (E. cloacae) meropenem D2 Yes 0.7 No 0.03 0.03 
            D3 Yes 0.9 No     
          ertapenem D2 Yes 0.3 No 0.012 0.12 
            D4 Yes 0.3 No     
61 M 20 #23 Pneumonia (oropharyngeal flora) amox-clav.  D2 No 3.1 ↓ Increase /   
            D3 No 2.4 ↓ AB switch     
      #24 Pneumonia (H. alvei) meropenem D1 No 2.8 No 0.03 0.03 
            D2 Yes 1.7 No     
            D4 Yes 3.3 No     
35 M 20 #25 Burn wound (S. bovis) amox-clav.  D3 No 0.8 ↓ Increase 0.25 0.312 
            D4 Yes 2.2 c ↓ Increase     
            D6 Yes 1.0 c ↓ No     
      #26 Pneumonia (E. aerogenes) pip-tazo D2 Yes 0.9 / 0.2 ↓ Increase 1.5 2.31 
            D4 Yes 1.7 / 0.3 d No     
            D6 Yes 1.1 / 0.2 ↓ No     
      #27 Catheter infection (K. pneumoniae) meropenem D2 Yes 0.3 No 0.03 0.03 
43 M 18 #28 Burn wound (P. aeruginosa) pip-tazo D2 No 1.8 / 0.4 ↓  Increase 1.5 2.31 
        
  
  D4 Yes 29.8 / 3.4 No     
        
  
ceftazidime D2 No 7.3 e No 2.0 2.5 
        
  
  D4 No 6.2 e No     
31 M 48 #29, #30 Burn wound and pneumonia (C. koseri) amox-clav.  D2 Yes 5.4 No 4.0 / 4.0 5.0 / 5.0 
        
  
  D4 Yes 3.2 ↓ No     
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  D6 Yes 7.6 No     
        
  
ceftriaxone D2 Yes 3.7 No 0.06 / 0.032 0.6 / 0.32 
      #31 Chronic pansinusitis acutised  meropenem D2 No 3.2 No / / 
        (non identified microorganism)   D3 No 1.1 ↓ Increase     
        
  
  D4 No 0.7 ↓ Already adapted     
        
  
  D6 No 5.7 No     
        
  
  D8 No 3.3 No     
        
  
  D10 No 7.5 No     
        
  
  D12 No 1.6 No     
          
  D14 No 1.8 No     
          
  D16 No 2.9 No     
      #32 Urinary tract (E. coli) ceftriaxone D2 Yes 8.4 No 0.12 1.2 
80 M 12 #33 Pneumonia (Enterobacteria) amox-clav.  D2 No 4.9 ↓ Increase / / 
            D4 No 11.4 No     
            D5 No 12.1 No     
            D6 No 9.7 No     
      
#34, 
#35 Burn wound and pneumonia (P. aeruginosa) pip-tazo D3 Yes 3.5 / 0.9 ↓ Increase 3.0 / 6.0 4.62 / 9.24 
            D4 Yes 1.3 / 0.4 ↓ Already adapted     
            D5 Yes 7.8 / 2.0 d No     
            D6 Yes / /     
31 M 63 #36 Pneumonia (S. aureus) ceftriaxone D2 Yes 18.7 d No 8.0 80 
            D4 Yes 15.7 d AB switch     
          amox-clav.  D2 Yes 1.0 ↓ AB switch 1.0 1.25 
          meropenem D1 No 0.3 ↓ Increase 0.12 0.12 
            D2 Yes 2.0 No     
      #37 Sepsis (non identified microorganism) meropenem D2 No 11.5 ↑ Decrease / / 
      #38 Pneumonia (S. aureus, K. pneumoniae) meropenem D1 No 10.3 ↑ Decrease 0.06 / 0.015 0.06 / 0.015 
          
  D2 Yes 4.0 No     
          
  D4 Yes 3.0 No     
Standard-of-care group 
69 F 10 #39 Pneumonia (S. pneumoniae) amoxicillin D2 Yes 4.3 Blinded TDM 0.032 0.04 
          
  D4 Yes 2.8 Blinded TDM     
          
  D6 Yes 1.6 Blinded TDM     
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  D8 Yes 1.5 Blinded TDM     
36 M 60 #40 Pneumonia (H. influenzae, E. coli) meropenem D2 No 0.8 ↓ Blinded TDM / / 
        
  amox-clav. D2 No 2.2 ↓ Blinded TDM 1.00 / - 1.25 / - 
      #41 Pneumonia (P. aeruginosa, E. cloacae)  meropenem D2 Yes / Blinded TDM 0.12 / 0.03 0.12 / 0.03 
          
  D4 Yes 0.2 Blinded TDM     
          
  D6 Yes 0.5 Blinded TDM     
          
  D8 Yes 4.3 Blinded TDM     
      #42 Ileal perforation  meropenem D10 No 46.5 ↑ Blinded TDM / / 
        (microoganism non identified)   D13 No 2.3 Blinded TDM     
          
  D14 No 3.8 No f     
          
  D16 No 30.1 ↑ Blinded TDM     
          
  D18 No 0.7 ↓ Increase f     
          
  D20 No 2.4 Blinded TDM     
      #43 Catheter infection (P. aeruginosa) ceftazidime D2 Yes 8.3 Blinded TDM 1.00 1.25 
          
  D3 Yes 0.5 ↓ Blinded TDM     
          
  D4 Yes 6.0 Blinded TDM     
          
  D6 Yes 4.3 Blinded TDM     
          
  D8 Yes 5.0 Blinded TDM     
      #44 Burn wound (P. aeruginosa) meropenem D2 Yes 0.4 ↓ Blinded TDM 2.00 2.00 
            D3 Yes 0.4 ↓ Blinded TDM     
            D4 Yes 0.5 ↓ Blinded TDM     
            
D6 Yes 1.3 ↓ Blinded TDM     
            
D8 Yes / Blinded TDM     
            
D10 Yes 3.4 Blinded TDM     
19 M 25 #45 Pneumonia (S. aureus) meropenem D2 No 0.7 ↓ Blinded TDM / / 
          
flucloxacillin D2 No / Blinded TDM 
not in 
routine  not in routine  
          
  D4 No / Blinded TDM     
          
  D6 No 8.9 ↓ Blinded TDM     
          
  D8 No 8.3 ↓ Blinded TDM     
          
  D10 No 3.7 ↓ Blinded TDM     
          
  D12 No 4.0 ↓ Blinded TDM     
          
  D14 No 5.3 ↓ Blinded TDM     
          
  D16 No 3.4 ↓ Blinded TDM     
          
  D18 No 4.2 ↓ Blinded TDM     
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  D20 No 2.9 ↓ Blinded TDM     
24 M 35 #46 Pneumonia (S. aureus, H. influenzae) amox-clav. D2 No 1.2 ↓ Blinded TDM 0.25 / - 0.312 / - 
          
  D4 No 0.7 ↓ Blinded TDM     
51 M 27 #47 Pneumonia (H. influenzae) ceftriaxone D1 Yes 14.0 Blinded TDM < 0.016 < 0.16 
            D2 Yes 11.3 Blinded TDM     
            D4 Yes 15.0 Blinded TDM     
            D6 Yes 62.6 Blinded TDM     
24 M 14 #48 Pneumonia (H. influenzae, S. aureus) ceftriaxone D2 No 6.0 ↓ Blinded TDM 0.016 / - 0.16 / - 
            D4 No 4.1 ↓ Blinded TDM     
57 M 12 #49 Burn wound (S. aureus, P. aeruginosa) pip-tazo D2 No 2.1 / 0.3 ↓ Blinded TDM - / 0.03 - / 0.046 
        
  
  D4 No 2.0 / 0.3 ↓ Blinded TDM     
53 F 12 #50 Urinary tract (P. mirabilis, E. faecalis) amox-clav. D2 No 3.7 ↓ Blinded TDM / / 
            D4 No 5.2 ↓ Blinded TDM     
            D6 No 4.6 ↓ Blinded TDM     
42 F 8 #51 Pneumonia (S. pneumoniae, S.aureus) amox-clav. D2 Yes 1.1 ↓ Blinded TDM 0.015 / 2.0 0.019 / 2.5 
            D4 Yes 2.7 Blinded TDM     
            D6 Yes 1.5 ↓ Blinded TDM     
            D8 Yes 1.3 ↓ Blinded TDM     
83 M 18 #52 Pneumonia (P. mirabilis, E.coli) meropenem D3 Yes 2.1 Blinded TDM 0.06 / 0.015  0.06 / 0.015 
            D4 Yes 42.7 ↑ Blinded TDM     
            D6 Yes 2.2 Blinded TDM     
      #53  Pneumonia  pip-tazo D1 No 38.4 / 6.7 ↑ Blinded TDM / / 
        (non identified microorganism)   D2 No 51.2 / 10.3 ↑ Blinded TDM     
            D4 No 49.6 / 3.5 ↑ Blinded TDM     
            D6 No / Blinded TDM     
            D8 No 39.5 / 9.1 ↑ Blinded TDM     
            D10 No 20.1 / 7.3 Blinded TDM     
      #54  Pneumonia  meropenem D2 No 3.9 Blinded TDM / / 
        (non identified microorganism)   D4 No 2.4 Blinded TDM     
25 M 70 #55 Urinary tract (E. faecalis) amoxicillin D2 Yes 2.2 Blinded TDM 0.5 0.625 
            D4 Yes 0.6 Blinded TDM     
            D6 Yes 1.8 Blinded TDM     
      
#56, 
#57 Burn wound and VAP (P. mirabilis, S. marcesens) meropenem D2 Yes 1.0 Blinded TDM 0.03 / 0.06 0.03 / 0.06 
          ertapenem D2 Yes 0.1 ↓ Blinded TDM 0.006 / 0.06 / 0.32 
 o
n
 February 6, 2018 by Universitaetsbibliothek Bern
http://aac.asm
.org/
D
ow
nloaded from
 
0.032 
            D4 Yes 0.1 ↓ AB switch f     
        
  
meropenem D1 Yes 1.0 No f 0.03 / 0.06 0.03 / 0.06 
        
  
  D2 Yes 0.6 Blinded TDM     
        
  
  D3 Yes 0.2 Blinded TDM     
        
  
  D4 Yes 0.5 Blinded TDM     
        
  
  D6 Yes 0.4 Blinded TDM     
      #58 Pneumonia (P. mirabilis) meropenem D1 No 11.7 ↑ Blinded TDM / / 
            D2 No 1.3 ↓ Blinded TDM     
        
  
ceftriaxone D3 Yes 7.5 Blinded TDM 0.19 1.9 
        
  
  D5 Yes 8.0 Blinded TDM     
        
  
  D6 Yes 5.9 Blinded TDM     
93✝ M 22 #59 Pneumonia (S. aureus) amox-clav.  D2 Yes 16.9 Blinded TDM 2.0 2.5 
            D4 Yes 17.3 Blinded TDM     
71 M 18 #60 Burn wound (E. coli, E. cloacae, S. aureus, P. vulgaris) meropenem 
D2 Yes 1.2 Blinded TDM 
0.015 / 
0.015 / 0.12 
/ 0.06 
0.015 / 0.015 / 
0.12 / 0.06 
17 M 64 #61, #62 Burn wound (E. faecalis) and peritonitis pip-tazo D2 No 20.3 / 2.4 Blinded TDM 1.5 / - 2.31 / - 
        
  
  D4 No 17.8 / 2.1 Blinded TDM     
        
  
  D6 No 14.6 / 2.2 No f     
        
  
  D8 No 12.9 / 2.2 Blinded TDM     
        
  
  D10 No 8.6 / 1.9 No f     
      #63 Pneumonia (K. oxytoca) meropenem D1 Yes 1.3 Blinded TDM 0.03 0.03 
        
  
  D2 Yes 1.7 Blinded TDM     
        
  
  D4 Yes 15.4 ↑ Blinded TDM     
        
  
  D6 Yes 3.1 Blinded TDM     
        
  
  D8 Yes 2.2 Blinded TDM     
      #64 Sepsis (non identified microorganism) meropenem D2 No 0.5 ↓ Blinded TDM / / 
            D3 No 0.5 ↓ Blinded TDM     
            D4 No 0.3 ↓ Blinded TDM     
            D6 No 0.4 ↓ Blinded TDM     
      #65 Pneumonia (K. oxytoca) meropenem D1 Yes 0.7 Blinded TDM 0.03 0.03 
          ceftriaxone D2 Yes 23.5 Blinded TDM 0.047 0.47 
            D4 Yes 39.4 Blinded TDM     
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16 M 55 #66 Bacteriema (Bacillus spp., G. adiacens) imipenem D2 Yes 1.4 / 0.8 g ↓ Blinded TDM 0.12 / > 32 0.15 / > 40 
        
    D4 Yes 1.6 / 1.0 g ↓ Blinded TDM     
        
  
  D6 Yes 1.9 / 0.9 g ↓ Blinded TDM     
        
  
  D8 Yes 2.5 / 1.5 g ↓ Blinded TDM     
          amox-clav.  D2 Yes / / 1.0 / 1.0 1.25 / 1.25 
            D3 Yes 0.7 ↓ Blinded TDM     
            D4 Yes 0.9 ↓ Blinded TDM     
      #67 Pneumonia (E. coli) pip-tazo D1 Yes 1.9 / 0.3 Blinded TDM 0.5 0.77 
            D2 Yes 3.9 / 0.7 Blinded TDM     
            D4 Yes 0.5 / 0.1 ↓ Blinded TDM     
            D6 Yes 1.0 / 0.2 Blinded TDM     
50 M 15 #68 Pneumonia (S. pneumoniae) amox-clav.  D2 Yes 0.4 Blinded TDM 0.015 0.019 
92 F 11 #69 Post grafting antibiotic amox-clav.  D2 No 9.6 Blinded TDM / / 
            D4 No 15.2 Blinded TDM     
      #70 Burn wound (P. aeuruginosa) pip-tazo D3 Yes 12.9 / 3.5 Blinded TDM 2.0 3.08 
            D4 Yes 12.7 / 3.4 Blinded TDM     
            D6 Yes 39.8 / 8.8 ↑ Blinded TDM     
62 F 36 #71 Pneumonia (E. coli) pip-tazo D1 Yes 3.4 / 0.7 Blinded TDM 0.75 1.16 
            D3 Yes 1.7 / 0.4 Blinded TDM     
            D4 Yes 7.0 / 1.3 Blinded TDM     
            D6 Yes 15.2 / 1.9  Blinded TDM     
            D8 Yes 14.0 / 1.9 Blinded TDM     
            D10 Yes 17.1 / 2.5 Blinded TDM     
          ceftriaxone D2 No 7.5 ↓ Blinded TDM / / 
83✝ F 35 #72 Pneumonia (Pantoea spp.) amox-clav.  D2 Yes 12.6 Blinded TDM 2.0 2.5 
            D4 Yes 7.7 Blinded TDM     
          ceftriaxone D2 Yes 28.0 Blinded TDM 0.03 0.3 
      #73 Post grafting antibiotic  amox-clav.  D2 No 11.7 Blinded TDM / / 
            D4 No 13.5 Blinded TDM     
            D6 No 11.4 Blinded TDM     
                        
F: Female; I : Intervention group; M: Male;  S: Standard-of- care group; SAPS II:  Simplified acute physiology score II; TBSA: Total Body Surface Area.     
* Since start of antibiotherapy               
** At the time of trough level interpretation             
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*** According to protein binding (see Suppl. Table 2 for more details)               
✝Death 
                
Black and bold : appropriate trough level               
Black and italic : not in the target trough level               
↑ Too high trough level               
↓ Too low trough level               
a
   Neurotoxicity  suspected               
b
 The TDM consultant took into account only one MIC               
c 
 The TDM consultant did not take into account the available MIC               
d
 The TDM consultant did not take into account the protein binding               
e
 Change on the antibiogram ( > 8 mg/L if no MIC)               
f
 Rescue TDM (unblinded trough level)               
g
 Inappropriate antibiotic (G. adiacens MIC > 32 mg/L)               
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Table 3: Infections characteristics and antibiotic levels results 
 
 
 
Infections characteristics and antibiotic levels results 
 
All patients 
Patients with unblinded 
TDM 
(Intervention group) 
Patients with blinded 
TDM 
(Standard-of-care group) 
Infection types 73 40 33 
Pneumonia 
Burn wound infection 
Sepsis of unknown origin 
Urinary tract infections 
Catheter related infection 
Peritonitis 
Post-grafting antibiotics 
Others 
42 (57.5) 
16 (21.9) 
4 (5.5) 
3 (4.1) 
2 (2.7) 
2 (2.7) 
2 (2.7) 
2 (2.7) 
22 (55.0) 
9 (22.5) 
3 (7.5) 
1 (2.5) 
1 (2.5) 
1 (2.5) 
2 (5.0) 
1 (2.5) 
20 (60.6) 
7 (21.2) 
1 (3.0) 
2 (6.1) 
1 (3.0) 
1 (3.0) 
0 
1 (3.0) 
Infection outcomes (n) 67* 36 31 
Resolved (n, %) 
Unresolved (n, %) 
63 (94.0) 
4 (6.0) 
33 (91.7) 
3 (8.3) 
30 (96.8) 
1 (3.2) 
Number of antibiotic levels 244 118 126 
Total number of appropriate antibiotic levels (n) Number 
of appropriate first antibiotic levels (n, %) Number of 
appropriate subsequent antibiotic levels (n, %) 
Not appropriate antibiotic levels (n) 
Below the predefined target (n, %) 
Over the predefined target (n, %) 
151/244 (61.9) 
46/82 (56.1) 
105/162 (64.8) 
92/244 (37.7) 
69/244 (28.3) 
23/244 (9.4) 
79/118 (66.9) 
22/41 (53.7) 
57/77 (74.0) 
38/118 (32.3) 
25/118 (21.2) 
13/118 (11.0) 
72/126 (57.1) 
24/41 (58.5) 
48/85 (56.5) 
54/126 (42.9) 
44/126 (34.9) 
10/126 (7.9) 
Analysis per TBSA 82 41 41 
In the target antibiotic levels (n, %) 
< 20% 
20-40 % 
> 40% 
Out of the target antibiotic levels 
< 20% 
20-40 % 
> 40% 
105 
29 
35 
41 
57 
16 
18 
23 
70 
20 (69.0) 
23 (65.7) 
14 (34.1) 
20 
5 (31.2) 
10 (55.6) 
5 (21.7) 
35 
9 (31.0) 
12 (34.3) 
27 (65.9) 
37 
11 (68.8) 
8 (44.4) 
18 (78.3) 
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 Number of cures (n) / Defined daily doses of antibiotics (n) 82 1468.8 41 731.1 41 737.7 
Amoxicillin (n, %) 
Meropenem (n, %) 
Flucloxacillin (n, %) 
Piperacillin-tazobactam (n, %) 
Ceftriaxone (n, %) 
Imipenem-cilastatin (n, %) 
Ceftazidime (n, %) 
Ertapenem (n, %) 
Cefazoline (n, %) 
22 (25.6) 726.7 (49.5) 
27 (32.9) 411.8 (28.0) 
2 (2.4) 121 (8.2) 
12 (14.6) 88.2 (6.0) 
12 (14.6) 61 (4.2) 
2 (2.4) 17.1 (1.2) 
2 (2.4) 17 (1.2) 
2 (2.4) 11 (0.7) 
1 (1.2) 15 (1.0) 
10 (24.4) 383.1 (52.4) 
14 (34.2) 239.3 (32.7) 
1 (2.4) 17 (2.3) 
6 (14.6) 33.9 (4.6) 
6 (14.6) 28.5 (3.9) 
1 (2.4) 5.8 (0.8) 
1 (2.4) 3.5 (0.5) 
1 (2.4) 5 (0.7) 
1 (2.4) 15 (2.1) 
12 (29.3) 343.6 (46.6) 
13 (31.7) 172.5 (23.4) 
1 (2.4) 104 (14.1) 
6 (14.6) 54.3 (7.4) 
6 (14.6) 32.5 (4.4) 
1 (2.4) 11.3 (1.5) 
1 (2.4) 13.5 (1.8) 
1 (2.4) 6 (0.8) 
0 0.0 
Appropriate antibiotic levels for the most used antibiotics    
Meropenem (n, %) 
Amoxicillin (n, %) 
Piperacillin-tazobactam (n, %) 
Ceftriaxone (n, %) 
43/63 (68.3) 
23/35 (65.7) 
17/28 (60.7) 
10/11 (90.9) 
28/36 (77.8) 
12/18 (66.7) 
4/9 (44.4) 
4/4 (100.0) 
15/27 (55.6) 
11/17 (64.79 
13/19 (68.4) 
6/7 (85.7) 
* =73 - (4 concomitant sites of infection + 2 post-grafting antibiotics) 
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